PLX Pharma
Houston, US · Delaware corporation
Founders & leadership
UM
GM
Gary MossmaninCOO
DJ
David JordenCFO, Secretary
MV
Michael ValentinoDirector, Executive Chairman
NG
Natasha GiordanoDirector, President, CEO
DL
David LuciNamed on SEC filing
JH
John HaddenNamed on SEC filing
Board
KC
Kirk CalhounBoard director
BC
Bob CasaleBoard director
GB
Gary BalkemaBoard director
RZ
Ron ZimmermanSenior Adviser
JH
John Hadden IIBoard director
Reported raises · per SEC filings
Form D private placements$60.5M disclosed across 5 rounds · 2016–2020
▶$18MraisedNov 2020 · 25 investors · PharmaceuticalsRule 506(b)
▶$18MraisedNov 2020 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Natasha GiordanoExecutive Officer, Director
- Rita O'ConnorExecutive Officer
- John W. Hadden IIDirector
- Anthony BartshDirector
- Kirk CalhounDirector
- Robert CasaleDirector
- Gary BalkemaDirector
- Michael J. ValentinoExecutive Officer, Director
- Offering amount
- $18M
- Amount sold
- $18M
- Sales commissions
- $1M
- Placement agents
- Raymond James & Associates, Inc.
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMay 2020 · 3 investors · PharmaceuticalsRule 506(b)
▶$8MraisedMay 2020 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Natasha GiordanoExecutive Officer, Director
- Gary BalkemaDirector
- Rita O'ConnorExecutive Officer
- Kirk CalhounDirector
- John W. Hadden IIDirector
- Anthony BartshDirector
- Michael J. ValentinoExecutive Officer, Director
- Robert CasaleDirector
- Offering amount
- $8M
- Amount sold
- $8M
- Sales commissions
- $120K
- Placement agents
- Raymond James & Associates, Inc.
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedMar 2019 · 2 investors · PharmaceuticalsRule 506(b)
▶$15MraisedMar 2019 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert CasaleDirector
- John W. Hadden IIDirector
- Gary BalkemaDirector
- Efthymios DeliargyrisExecutive Officer
- Kirk CalhounDirector
- Michael J. ValentinoExecutive Officer, Director
- Natasha GiordanoExecutive Officer, Director
- Rita O'ConnorExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- Sales commissions
- $1.1M
- Placement agents
- JMP Securities LLC
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.2MraisedJun 2017 · 37 investors · PharmaceuticalsRule 506(b)
▶$18.2MraisedJun 2017 · 37 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David JordenExecutive Officer
- David LuciDirector
- Robert CasaleDirector
- Gary BalkemaDirector
- Natasha GiordanoExecutive Officer, Director
- Michael J. ValentinoExecutive Officer, Director
- Gary MossmanExecutive Officer
- John HaddenDirector
- Kirk CalhounDirector
- Offering amount
- $18.2M
- Amount sold
- $18.2M
- Sales commissions
- $1.2M
- Placement agents
- Raymond James & Associates, Inc., Janney Montgomery Scott LLC
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMar 2016 · 27 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedMar 2016 · 27 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Upendra MarathiExecutive Officer
- Kirk CalhounDirector
- Bob CasaleDirector
- Gary BalkemaDirector
- Gary MossmanExecutive Officer
- Ron ZimmermanExecutive Officer
- David JordenExecutive Officer
- John Hadden IIDirector
- Michael ValentinoDirector
- Natasha GiordanoExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.3M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has PLX Pharma raised?
- PLX Pharma has disclosed $60.5M raised across 5 rounds.
- Where is PLX Pharma headquartered?
- PLX Pharma is headquartered in Houston, US.